Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 6/20 | 0.56 |
| ▸ | CCR2 | P41597 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RHEB | Q15382 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300781 | 0.89 | CCR2 (0.53) | CCR9CCR2RHEB | |
| SCHEMBL6300706 | 0.88 | CCR9 (0.53) | CCR9CCR2RHEB | |
| SCHEMBL4214845 | 0.81 | CCR9 (0.59) | CCR9CCR2 | |
| SCHEMBL6303493 | 0.80 | CCR2 (0.62) | CCR9CCR2RHEB | |
| SCHEMBL4198698 | 0.80 | CCR2 (0.71) | CCR9CCR2MEN1KMT2A | |
| SCHEMBL13802530 | 0.78 | CCR2 (0.50) | CCR9CCR2MEN1KMT2A | |
| SCHEMBL701444 | 0.77 | GPR35 (0.46) | CCR9CCR2MEN1KMT2ARHEB | |
| SCHEMBL7079495 | 0.76 | CCR2 (0.47) | CCR9CCR2RHEB | |
| SCHEMBL13802529 | 0.76 | CCR2 (0.55) | CCR9CCR2 | |
| SCHEMBL6300529 | 0.75 | CCR2 (0.49) | CCR9CCR2RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | CCR9 2109/4885CCR2 1386/4885MEN1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.